produced by a simple horizontal infection. These viruses can be transmitted vertically (that is, inherited) after they have been incorporated into the host genome, and the infections they cause tend to have very long latent periods. Though leukaemia is rare in childhood, C-type viruses are probably widely distributed; so other infrequent host factors would have to come into play to allow the viruses to escape from being repressed. Such factors probably include heredity,8 exposure to physical or chemical agents (such as radiation9 or cytotoxic drugs3), and temporary alteration ofimmunity as might occur after infection with a non-oncogenic virus. In lymphoblastic leukaemia, such a factor might mediate its effect through the loss of a functional lymphocyte suppressor cell population, which theoretically might either fail to control aberrant malignant lymphoproliferation or alternatively, lead to increased autoimmune disease.10 Both are frequently observed in New Zealand mice, which lose such suppressor functions for both B and T cell activities spontaneously early in life. Interestingly, the firstdegree relatives of children with lymphoblastic leukaemia have an increased incidence of autoimmune disease. '1 The question posed in the title of this article cannot be answered. Information is slowly accumulating to indicate that C-type or similar viruses play at least some part in some cases of childhood leukaemia, but their role does not appear simple and may prove similar to an explosive charge which requires an unusual set of circumstances for detonation. Wang A further major advance was the introduction of the anthracycline antibiotics daunorubicin and doxorubicin. These drugs are chemically and pharmacologically closely similar and act by inhibiting replication of DNA. Complete remission rates of up to 500 ' have been seen when anthracyclines have been used as single agents5-10 (table I) .
Modern treatment logically combines the purine antagonist 6-thioguanine and ara-C, in courses of five to seven days, with daily intravenous daunorubicin or doxorubicin for one to three days (table II) . Ara-C is now often given as a continuous intravenous infusion, though its toxicity is probably less when Ara-C 100 mg/m2 day 1-7 (iv infusion) 82% DNR 60 mg m' day [5] [6] [7] Gale and Cline (1977)" Ara-C 100 mg m2 bd day 1-7 TG 100 mg/mi bd day [1] [2] [3] [4] [5] [6] [7] 85 O DNR 50 mg/m`day 1 Rees et al (1977)15 Ara-C 100 mg iM2 bd day 1-5 TG 100 mg 'm2 bd day [1] [2] [3] [4] [5] 1972 and 1978 went on to develop central nervous system leukaemia), and, because of this low incidence and the relatively short survival of most 1 1 OCTOBER 1980 patients with acute myelogenous leukaemia, prophylactic treatment cannot be recommended as a routine. The observation that clinically inapparent central nervous system leukaemia occasionally occurs in patients with acute myelogenous leukaemia31 lends support, however, to periodic examination of the cerebrospinal fluid.
Bone marrow transplantation-Two relatively recent additions to the treatment of acute myelogenous leukaemia are allogeneic bone marrow transplantation from an HLAidentical sibling and the transplantation of autologous cryopreserved bone marrow collected during remission.
plantation should be given serious consideration soon after a first remission has been induced-a policy which can be justified on economic grounds. 37 Autologous bone marrow transplantation has recently been tried in small numbers of patients.38 39 Bone marrow is collected from patients in their first remission and cryopreserved. At the time of relapse, patients receive marrow ablation similar to that used for allogeneic bone marrow transplantation followed by infusion of their own stored, reconstituted bone marrow. The results are preliminary, but long disease-free survival has been reported for occasional Supportive care-When they first present most patients with acute myelogenous leukaemia are prone to bleeding by virtue of platelet counts below 50 x 109/1 and to infection from their granulocyte counts if fewer than 1 x 109/1. These counts are soon reduced further by chemotherapy, and most of the recent improvements in survival have been possible only because of advances in the management of bleeding and infection.
Skin petechiae and minor episodes of bleeding in the fundi, mouth, and gut become common when platelet counts fall below 20 x 109/1, but these symptoms can usually be controlled by intravenous infusion of platelets from random donors. The platelets are prepared from fresh blood as platelet-rich plasma or a platelet concentrate. Platelet concentrate is better than platelet-rich plasma because of the danger of circulatory overload with large volumes of plasma. The platelets from four to six units of blood are usually given once daily until bleeding stops. With the use of platelets taken from random (HLA-mismatched) donors, up to half the patients treated develop platelet antibodies,40 41 so that the prophylactic use of platelet transfusion cannot be recommended. Immunisation can be overcome if HLA-matched platelets are used,42 but such a programme depends on the availability of tissue-typing facilities and, if it is to be practicable, requires facilities for collecting large numbers of platelets from a single donor by plateletpheresis and their cryopreservation. Where typing facilities are not freely available an alternative is to collect platelets for immediate use from the patient's siblings or other close relatives on the assumption that they will be partly HLA matched.
Acute promyelocytic leukaemia is particularly associated with bleeding due to disseminated intravascular coagulation, so much so that prophylactic low-dose heparin has been used successfully. 43 The use of platelet transfusion has reduced deaths from haemorrhage, but this has been accompanied by an increase in the number of deaths associated with infection, partly related to the severe neutropenia caused by increasingly intensive chemotherapy. The impaired immunity and the neutropenia associated with the leukaemia are other important predisposing factors. Infections of the mouth and the upper respiratory tract and pneumonia are particularly common, while infections of the skin and urinary tract and perianal abscesses are frequent. These and infection through unidentified portals of entry are associated with a high incidence of systemic sepsis, of which more than half is due to Gramnegative organisms, especially Escherichia coli, Klebsiella 
